Table 1 Basic characteristics of the included literature
Author | Year | Study period | Region | Study design | Registration number | Population | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Bamias et al. | 2024 | 2016–2018 | Greece | RCT | NCT02807636 | locally advanced or metastatic urothelial cancer | ||||
Bellmunt et al. | 2021 | 2015–2018 | USA | RCT | NCT02450331 | high-risk muscle-invasive urothelial carcinoma | ||||
Fukuokaya et al. | 2024 | NA | Japan | RCT | NCT02108652 NCT02302807 | locally advanced or metastatic urothelial cancer | ||||
Galsky et al.[1] | 2020 | 2016–2018 | USA | RCT | NCT02807636 | locally advanced or metastatic urothelial cancer | ||||
Galsky et al.[2] | 2020 | 2016–2018 | USA | RCT | NCT02807636 | locally advanced or metastatic urothelial cancer | ||||
Grande et al. | 2024 | 2016–2018 | Spain | RCT | NCT02807636 | locally advanced or metastatic urothelial cancer | ||||
Grande et al. | 2023 | NA | Spain | RCT | NCT02807636 | metastatic urothelial cancer | ||||
Powles et al. | 2018 | 2015–2016 | UK | RCT | NCT02302807 | locally advanced or metastatic urothelial cancer | ||||
Sotelo et al. | 2020 | NA | Spain | RCT | NCT02108652 NCT02302807 | locally advanced or metastatic urothelial cancer | ||||
Heijden et al. | 2021 | 2015–2018 | Netherland | RCT | NCT02302807 | locally advanced or metastatic urothelial cancer | ||||
Author | Intervention | Control | Patients | Median follow-up (month) | Mean/median age | Male | Outcome | |||
Intervention | Control | Intervention | Control | Intervention | Control | |||||
Bamias et al. | Atezo (1200mg/every 3 weeks) | placebo + chemo | 360 | 359 | 13.4 | 67 | 66 | 279 | 264 | OS |
Bellmunt et al. | Atezo (1200mg/every 3 weeks) | observation | 406 | 403 | 21.9 | 67 | 66 | 322 | 316 | OS |
Fukuokaya et al. | Atezo (1200mg/every 3 weeks) | chemo | 855 | 426 | 11 | 67 | 67 | 665 | 332 | OS |
Galsky et al.[1] | Atezo (1200mg/every 3 weeks) + Chemo(1000mg/every 1 weeks) | placebo + chemo | 451 | 400 | 11.8 | 69 | 67 | 338 | 298 | OS |
Galsky et al.[2] | Atezo (1200mg/every 3 weeks) | placebo + chemo | 360 | 400 | 11.8 | 67 | 67 | 280 | 298 | OS |
Grande et al. | Atezo (1200mg/every 3 weeks) + Chemo(1000mg/every 1 weeks) | placebo plus chemo | 451 | 400 | 13.4 | NA | NA | 339 | 298 | OS |
Grande et al. | Atezo (1200mg/every 3 weeks) + Chemo(1000mg/every 1 weeks) | placebo plus chemo | 257 | 245 | 13.4 | 69 | 67 | 199 | 182 | OS |
Powles et al. | Atezo (1200mg/every 3 weeks) | chemo | 467 | 464 | 17.3 | 67 | 67 | 357 | 361 | OS |
Sotelo et al. | Atezo (1200mg/every 3 weeks) | chemo | 74 | 53 | NA | 68 | 66 | 61 | 47 | OS |
Heijden et al. | Atezo (1200mg/every 3 weeks) | chemo | 467 | 464 | 33 | NA | NA | NA | NA | OS |